SEBELIPASE ALFA NEW THERAPY OF CHOICE FOR WOLMAN DISEASE release_66afvys2xzcqfighcwu3t6iqje

by Harinath Jolapuram Soumya Mula

Published by Zenodo.

2019  

Abstract

<em>Lysosomal enzyme activity deficiency(LAL-D) is a rare disorder of cholesterol metabolism of cellular steroid alcohol and for the physiology of lipoprotein diseases. When deficient in lysosomal acid </em><em>lipase</em><em>( </em><em>LAL), the enzyme results in deposited with steroid alcohol and triglycerides in a specific number of tissues. Future clinical results of adult and LAL patient medical care were assessed mainly using advantages of Sebelipase Alfa medical services that improve quality and life by examining several papillary diseases. Square measures were used to evaluate the clinical results of Sebelipase Alfa medicine. There is no cure, in particular, ongoing trails to enhance the sebelipase generation. Supportive management with lipid-modifying agents does not ameliorate disease progression. Hematopoietic stem cell transplantation as a curative measure in infantile disease has mixed success and is associated with inherent risks , complications and liver transplantation complexity by comparing the methods. Sebelipase was proved to be long term therapy for affected individuals. </em><em>(Kanuma) is the human LAL protein recombinant and the first LAL-D treatment was enzyme replacement therapy. In infants with rapid progressive LAL-D adults and children with later -onset LAL-D, clinical studies were undertaken.There is no cure to particular disease but it can increase life expectancy of affected patient.</em> <strong>Key Words</strong>: <em>lysosomal acid lipase, </em><em>cholesteryl esters</em><em>, triglycerides, calcification, Kanuma</em>
In text/plain format

Archived Files and Locations

application/pdf  695.0 kB
file_bwev2oxsmzcnndn2rd4ieghv34
zenodo.org (repository)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2019-08-29
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 96341880-eb99-4146-880c-4b4b3f443c32
API URL: JSON